10-Q · May 12, 2026
Mereo BioPharma reported a significant reduction in net loss to $6.7 million in Q1 2026 from $12.9 million in Q1 2025, owing to decreased operating expenses and improved foreign currency gains. Though cash declined from…
Earnings analysis · 10-Q
MREO earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text is limited to Items 3 through 6 and signatures, so it does not provide the financial statements or MD&A needed to assess revenue, margins, EPS, segment performance, liquidity, or cash flow.…
Read full summary
The supplied 10-Q text is limited to Items 3 through 6 and signatures, so it does not provide the financial statements or MD&A needed to assess revenue, margins, EPS, segment performance, liquidity, or cash flow. Management reported effective disclosure controls as of June 30, 2026 and no material control or legal-proceeding developments during the quarter. Risk factors were unchanged from the 2025 Annual Report, and no quantitative guidance is included in the provided excerpt.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
No material control changes
No changes in internal control over financial reporting occurred during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, controls.
-
No new legal developments
The filing reports no material developments in legal proceedings during the quarter ended June 30, 2026.
What to watch
-
Risk factors unchanged
The company states that there have been no material changes from the risk factors previously disclosed in its 2025 Annual Report; therefore, the filing provides no updated quantified risk assessment.
-
Core financial data unavailable
The provided filing excerpt does not include the income statement, balance sheet, cash flow statement, or MD&A, so revenue, profitability, liquidity, and operating-cash-flow trends for the three months ended June 30, 2026 cannot be verified from the 10-Q text supplied.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. The filing states that no material changes occurred in risk factors previously disclosed in the 2025 Annual Report.
Earlier filings 4
10-K · March 19, 2026
Mereo is a clinical-stage biopharmaceutical company focused on rare-disease therapeutics, centered on two late‑stage programs (setrusumab for OI and alvelestat for AATD‑LD) and a partner-funded early program…
10-Q · August 12, 2025
Mereo reported $500,000 of revenue in Q2 2025 (a $0.5M milestone) and a Q2 net loss of $14.616M (loss per share $0.02), compared with a net loss of $12.255M in Q2 2024. Cash declined to $56.125M at June 30, 2025 from…
10-K · March 26, 2025
Mereo positions itself as a rare-disease-focused biopharma that acquires de-prioritized, late-stage assets and advances them to pivotal studies. The 10-K emphasizes two core rare-disease candidates — setrusumab and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.